The COVID-19 pandemic has heightened interest in mHealth and mobile technology to capture patient insights outside of the traditional clinical setting.
Overview
Although mHealth devices and sensors are continuing to evolve, and it is now possible to capture a vast array of physiological data, the operationalisation of a digital trial is not without challenges.
Now more than ever there is a need to generate data from connected devices that are robust, reliable, and relevant, of sufficient quality and ensuring minimal data loss. At the heart of the decision to use a digital device in a clinical programme is the study objective. However as more of these technologies are being used in clinical studies questions are arising as to how to ensure that the data generated by these devices can be validated and used to support endpoints.
We will propose that the application of COA principles and techniques can be applied to build the evidence package, when considering, the evidence required to support digital endpoints for their submission to regulatory bodies and reimbursement stakeholders.
In this webinar we will
- Present a strategy to identify devices that are “fit for purpose”.
- Outline a framework for Digital Endpoint selection and validation to ensure the outcome measurement is robust, reliable, and interpretable.
- Address the key considerations that arise when using digital technology to support endpoint generation in clinical studies such as Device Selection, Endpoint Reliability and Sensitivity, Meaningful Change Thresholds, and Analysis Strategy and Interpretation.
Target audience
- Clinical Operations
- COA / eCOA
- Real World Evidence
On-Demand Webinar Archive
To access the archived recording of this webinar, visit our webinar channel and complete a one time only form. This will give you access to our entire library of archived webinars.
Presenters
Rachel Ballinger
Rachel has over 20 years research experience, mainly using qualitative and survey methods. She is currently serving on the ISPOR Performance Outcome Assessment Taskforce.
Since joining 91黑料 in December 2011 she has been working as a Project Director and formerly as Project Manager to undertake various studies such as utility studies; assessment of health related impacts on carers and of non-consented medication changes; validation of performance based measures; and in-depth review of COA measures. She has also contributed to FDA dossier development, qualitative research of patient-relevant endpoints and supported numerous other studies via interviewing, literature reviewing and manuscript writing.
Prior to Oxford Outcomes Rachel worked for six years as a Research Fellow at the Cancer Research UK Sussex Psychosocial Oncology Group, University of Sussex. Rachel has a PhD in Medical Sociology focusing on the interplay of different types of knowledge about childhood asthma.
Hannah Lewis
Hannah is a skilled and strategic outcomes research consultant, with experience in Clinical Outcome Assessment (COA) development and validation, strategic consultancy projects, COA quantitative data analysis, patient surveys, and preference studies.
Her research experience has spanned numerous therapeutic areas including appetite, obesity, nutrition, diabetes, endocrinology, infectious diseases, immunology, gastroenterology, oncology, respiratory, rare diseases, aesthetics, haematology and eating behaviour.
Hannah has vast experience in a wide range of statistical analyses including psychometric evaluation and estimation of clinically meaningful change for COA instruments. Prior to joining 91黑料, Hannah worked in public health research and completed a Ph.D. at the University of Cambridge, Gonville and Caius College, funded by a UK Medical Research Council scholarship. Hannah also holds a BSc. (Hons.) in Biology from the University of Bath, and an MSc. in Nutrition from King’s College London.
On-demand webinar archive
For access to 91黑料's other archived webinar recordings, complete the one-time only form seen on our . This will give you access to our entire library of archived webinars.